Plasma-Derived Therapies Investor Event

from the beginning

Leading Sustainable Growth Through End-to-End Innovation

@ Important Notice

• Our team

What we will cover today

• Our industry-leading performance has delivered for patients, demonstrating we have the right strategy, the right team and the right capabilities in place

• We achieved our capacity expansion target one year early through targeted investment in new and upgraded manufacturing infrastructure

• This achievement was bolstered by strategic investment and technologyled transformation across our BioLife plasma donation network

• Our outstanding revenue growth shows the strength of our broad and differentiated portfolio

• Our sustained portfolio growth is fueled by our patient-focused approach and strong momentum in R&D

• Data, Digital & Technology is driving innovative transformation across the value chain, bringing excellence, agility and efficiencies

• We have delivered greater efficiencies and higher revenue growth with less capacity than our peers through operational excellence and transformation

• Our FY2023 PDT BU guidance is confirmed by robust H1 financial results

We will continue to power up sustainable growth through endto-end innovation

• Significant unmet patient needs across many chronic and rare diseases are driving sustained PDT market growth despite headwinds

• We have set a new target to increase manufacturing capacity by >50% from FY2023 to end of FY2028

• We are taking a holistic approach to increasing plasma donation that is redefining industry standards and bringing greater efficiencies

• Our PDT portfolio strategy is positioned to drive sustainable long-term growth in a dynamic market through innovations that address unmet patient needs

• Long-term IG growth potential remains strong despite the entry of new modalities in neuroimmunology indications

• We are proud of our sustained success - and our planned investment underscores our confidence and drives our continued commitment to creating value

@

@ Glossary of Terms (In Alphabetical Order)

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6